195 related articles for article (PubMed ID: 9653495)
1. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
Borner MM; Castiglione M; Bacchi M; Weber W; Herrmann R; Fey MF; Pagani O; Leyvraz S; Morant R; Pestalozzi B; Hanselmann S; Goldhirsch A
Ann Oncol; 1998 May; 9(5):535-41. PubMed ID: 9653495
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H
Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Scheithauer W; Depisch D; Kornek G; Pidlich J; Rosen H; Karall M; Prochaska M; Ernst A; Sebesta C; Eckhardt S
Cancer; 1994 Mar; 73(6):1562-8. PubMed ID: 8156482
[TBL] [Abstract][Full Text] [Related]
7. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
[TBL] [Abstract][Full Text] [Related]
11. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
14. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
[TBL] [Abstract][Full Text] [Related]
15. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Kabbinavar F; Hurwitz HI; Fehrenbacher L; Meropol NJ; Novotny WF; Lieberman G; Griffing S; Bergsland E
J Clin Oncol; 2003 Jan; 21(1):60-5. PubMed ID: 12506171
[TBL] [Abstract][Full Text] [Related]
16. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
18. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Kalofonos HP; Skarlos D; Bafaloukos D; Papakostas P; Bamias A; Janinis J; Timotheadou E; Kouvatseas G; Stavropoulos M; Economopulos T; Fountzilas G
Cancer Invest; 2003; 21(6):855-62. PubMed ID: 14735689
[TBL] [Abstract][Full Text] [Related]
19. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Goldberg RM; Hatfield AK; Kahn M; Sargent DJ; Knost JA; O'Connell MJ; Krook JE; Maillard JA; Wiesenfeld M; Schaefer PL; Tirona MT; Moertel CG
J Clin Oncol; 1997 Nov; 15(11):3320-9. PubMed ID: 9363861
[TBL] [Abstract][Full Text] [Related]
20. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
